MARATTO

article · Alfarama Journal of Basic & Applied Sciences

Study of the Role of Migration Inducting Gene 7 as a Molecular Marker for Early Detection of Endometrial Carcinoma Micrometastasis.

2024Open accessPort Said University

Abstract

Background and objectives: Endometrial carcinoma diagnosed early by abnormal uterine bleeding especially in postmenopausal women. Migration-Inducting Gene 7 (MIG-7) is a cysteine-rich protein first identified in endometrial cancer cells upon hepatocyte growth factor (HGF) treatment.Subjects and methods: This case-control study was carried out in Mansoura University, Egypt on a total of 75 patients with 25 age-matched healthy female volunteers as control group and 50 patients classified according to standard criteria based on data of International Federation of Gynecology and Obstetrics (FIGO) into two groups (non-metastatic endometrial carcinoma and metastatic endometrial carcinoma). Total RNA extracted from peripheral blood, cDNA synthesized from RNA and Real-time PCR done for quantification of MIG7.Results: Comparison between the control group, patient with non-metastatic endometrial carcinoma and patient with metastatic endometrial carcinoma with regard to MIG7 gene expression reveal highly significant differences ((0.69±0.21), (1.38±0.39) and (1.97±0.45)) respectively, P-values (all˂ 0.001). AUC values for MIG7 equal 0.945 while MIG7 show sensitivity percentage of 88% and 88% specificity percent.In the univariable analysis MIG7 gives an odds ratio (ORs) 1.077 at p-values of 0.002 while in the multivariable analysis demonstrate elevated ORs, p-values (0.024).

Research topics

  • Macrophage Migration Inhibitory Factor
  • Biomarkers in Disease Mechanisms

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/ajbas.2024.292248.1213

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.